Strategic Collaboration with UK-Based GlycanAge
ExoEarth Corporation has initiated a strategic collaboration under a Memorandum of Understanding (MOU) with UK-based GlycanAge Ltd., which provides biological age testing using glycans worldwide.
The companies are working to expand access to GlycanAge testing in Japan and planning longitudinal collaborative research connecting glycan biomarkers with extracellular vesicle (EV) research.
1. Two Pillars of the Collaboration
Current Activities | Expanding Access to GlycanAge Testing in Japan
Under its MOU with GlycanAge, ExoEarth is working to expand opportunities for GlycanAge testing in Japan.
We share an approach that treats test results as indicators for understanding one's condition, informing everyday choices and following changes over time, rather than as isolated numbers.
Future Plans | Collaborative Research Linking Glycan Biomarkers and EV Science
The companies are planning longitudinal collaborative research linking GlycanAge's glycan biomarkers with ExoEarth's EV research.
Specific study designs will be determined following the necessary scientific, medical, ethical and regulatory review.
2. Roles of the Two Companies
| Organization | Role |
|---|---|
| GlycanAge | Provides technology and knowledge in IgG glycan-based GlycanAge testing and glycan science, and participates in expanding access in Japan and planning collaborative research. |
| ExoEarth | Works to expand access to GlycanAge testing in Japan and plans collaborative research connecting EV research and glycan biomarkers. |
3. GlycanAge Testing within MEASURE
GlycanAge testing analyzes glycans attached to immunoglobulin G (IgG) in blood.
IgG glycan patterns have been reported to vary in association with age, immune and inflammatory regulation, and lifestyle-related factors.
GlycanAge analyzes these patterns to assess characteristics associated with inflammaging and immune health.
ExoEarth positions GlycanAge testing as one measurement option within MEASURE in the HUMAN OS UPDATE longevity cycle.
We aim to use results as indicators for understanding the body's condition and to inform subsequent strategies and actions by tracking changes through repeated measurement.
4. What GlycanAge Can and Cannot Tell You
| What It Can Tell You | What It Cannot Tell You |
|---|---|
|
|
A GlycanAge value is not the age of the entire body. It is an indicator of one aspect of immune and inflammatory regulation reflected in IgG glycans.
It is important to follow changes in the same individual over time, rather than drawing conclusions from a single ranking.
Repeated measurement is used to track changes in an individual's results. Since multiple factors may contribute, changes in measurements alone cannot establish the effects of a particular activity.
5. Longitudinal Collaborative Research Concept
Under their MOU, the companies are planning longitudinal collaborative research using GlycanAge testing.
The proposed research would examine how biological age and immune-related indicators associated with EXOCURE-related programs change over time.
Participant numbers, measurement intervals, intervention conditions, research governance and other specific study details will be determined following the necessary scientific, medical, ethical and regulatory review.
6. Takashi Nishihira's Repeated Measurements and GlycanAge Champion 2026
ExoEarth Representative Director Takashi Nishihira, aged 67 at the time of the award, has continued GlycanAge testing since his sixties.
On June 20, 2026, he was selected as GlycanAge Champion 2026 – Immune Health Champion at GlycanAge's international event in Dubrovnik, Croatia.
The results announced at the time of the award were as follows.
| Chronological Age at Sample Collection | GlycanAge Measurement Result | Age Gap | Percentile Rank |
|---|---|---|---|
| 66 years | 20 years | −46 years | Top 1% |
This experience of repeated measurement is one of the origins of ExoEarth's envisioned longevity cycle.
Note: This award and these measurements concern Takashi Nishihira's personal results and ongoing efforts. They do not demonstrate medical or rejuvenation effects of any particular product or service, or the outcomes of collaborative research.
7. International Announcement and Coverage
The collaboration was announced internationally from London, UK, on August 20, 2026.
Following the announcement, it has been covered and introduced by overseas media and specialist information websites in EVs, longevity, health tech and biotechnology.
- EIN Presswire: Distributed the international announcement of the collaboration
- Exosome RNA: Coverage on a specialist EV information website
- Longevity Now: Summary and Editor's Insight from a Korean longevity publication
- IT Business Today: Coverage from a health tech and biotechnology perspective
- CB Insights: Included in “Latest GlycanAge News” in the company and market information database
8. Related Links and Contact
- Press Release dated September 8, 2026 (PDF)
- GlycanAge Official Website
- GlycanAge Champion Page
- ExoEarth Contact Form (GlycanAge, this collaboration, collaborative research and business partnerships)
Notes
Note: GlycanAge testing assesses biomarkers associated with biological age, immunity and inflammation. It is not intended to diagnose, treat or prevent a specific disease.
Note: Statements on this page about EXOCURE-related programs and EVs do not guarantee or imply efficacy, safety, treatment effects or rejuvenation effects for any specific disease.
Note: Specific collaborative research activities will be determined following the necessary scientific, medical, ethical and regulatory review.

